Molecular Templates, Inc. Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Components

3 Months Ended

Mar. 31, 2019

NOTE 6 — BALANCE SHEET COMPONENTS

Accrued liabilities were comprised of the following (in thousands):

	March 31,		December 31,
	2019		2018
Accrued liabilities:
General and administrative	$	440	$	297
Clinical trial related costs		889		598
Non-clinical research and manufacturing operations		3,788		2,644
401(k) contributions payable		19		—
Payroll related		828		1,787
Other accrued expenses		15		31
Total accrued liabilities	$	5,979	$	5,357

Deferred revenue was comprised of the following:

	March 31,		December 31,
	2019		2018
Deferred revenue:
Grant agreements	$	—	$	—
Research and development agreements		21,372		28,901
Total deferred revenue	$	21,372	$	28,901

Other assets include $3.0 million of restricted cash as of March 31, 2019.